



HAL
open science

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Hong S. Lee, Stephan Ripke, Benjamin M. Neale, Stephen V. Faraone, Shaun M. Purcell, Roy H. Perlis, Bryan J. Mowry, Anita Thapar, Michael E. Goddard, John S. Witte, et al.

► To cite this version:

Hong S. Lee, Stephan Ripke, Benjamin M. Neale, Stephen V. Faraone, Shaun M. Purcell, et al.. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nature Genetics*, 2013, 45 (9), pp.984-994. 10.1038/ng.2711 . inserm-00864642

HAL Id: inserm-00864642

<https://inserm.hal.science/inserm-00864642>

Submitted on 28 Mar 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Cross-Disorder Group of the Psychiatric Genomics Consortium

Correspondence to

Naomi R. Wray

The University of Queensland, Queensland Brain Institute, Brisbane, QLD, 4067 Australia.

naomi.wray@uq.edu.au

Summary paragraph

Most psychiatric disorders are moderately to highly heritable. The degree to which genetic variation is unique to individual disorders versus shared across disorders is unclear. We use genome-wide genotype data from the Psychiatric Genomics Consortium (PGC) of cases and controls for schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). We apply univariate and bivariate methods for estimation of genetic variation within and covariation between disorders. SNPs explained 17-29% of the variance in liability. The genetic correlation calculated from common SNPs is high for SCZ/BPD ($0.68 \pm SE 0.04$), moderate for SCZ/MDD (0.43 ± 0.06), BPD/MDD (0.47 ± 0.06), ADHD/MDD (0.32 ± 0.07), low between SCZ/ASD (0.16 ± 0.06), and non-significant for other pairs of disorders as well as with the negative control of Crohn's Disease. This empirical evidence for a shared genetic etiology between psychiatric disorders can inform nosology and encourages investigation of common pathophysiologies for the related disorders.

Text

Current classification of psychiatric disorders reflects clinical syndromes with largely unknown etiology and is based on historical descriptions provided by prominent clinicians over the last 125 years. Family (including twin and adoption) studies provide consistent evidence that genetic factors are involved in these syndromes¹. In principle, family studies allow quantification of shared genetic etiology, through estimation of heritability (the proportion of variance in liability attributable to additive genetic factors) of disorders and the genetic correlation between them. However, difficulties in ascertaining samples of sufficient size mean that estimates of genetic correlations are few. Nonetheless, family studies suggest correlated familial-genetic liabilities to BPD and SCZ^{2,3}, BPD and MDD^{2,3} and ASD and ADHD⁴⁻⁶ (**Supplementary Table 1**). Phenotypic and genetic overlap has also been suggested for ASD and SCZ⁷⁻¹¹, ASD and BPD⁹, BPD and ADHD¹² and MDD and ADHD¹³. Some of these relationships have been supported by recent evidence of shared molecular risk factors¹⁴⁻¹⁶, but the extent of these relationships remains unclear given the small proportion of risk associated with these individually identified variants.

The genomics era provides new opportunities to explore the shared genetic etiology of disorders. Genome-wide association studies (GWAS) assess common genetic polymorphisms (e.g., SNPs) at several hundred thousand positions in the genome. The experimental paradigm of GWAS is identification of individual variants associated with case-control status¹⁷. However, these data can be used to estimate the total variance in liability explained by SNPs ("SNP-heritability", $SNP-h^2$) through estimation of genetic similarities (relationships) between cases and controls using SNP genotypes^{18,19}. The pair-wise genetic relationships that contribute to the estimate are very small, but the large number of pairwise relationships in a case-control sample generates estimates with reasonable precision. The

$SNP-h^2$ is an estimate of the total variance in liability to disease explained by the SNPs together. Genetic variation is estimated when case-case pairs and control-control pairs are, on average, more similar genome-wide than case-control pairs. The $SNP-h^2$ is a lower bound for the total narrow sense heritability, as the former cannot include contributions from causal variants not tagged by the measured SNPs, mostly less common and rare causal variants. A bivariate extension²⁰ of these genome-wide methods estimates the genetic correlation ($SNP-r_g$) explained by SNPs between case-control samples collected independently for two disorders (see **online Methods**). The correlation is positive when the cases of one disorder show higher genetic similarity to the cases of the other disorder than to their controls. A negative correlation is possible if the cases of one disorder are less similar genome-wide to the cases of the other disorder than they are to controls. A genetic correlation of zero is estimated if the genome-wide relationship between cases of one disorder is the same with cases as with controls of the other disorder. As a correlation, a high $SNP-r_g$ is achieved when the covariance term between the traits is similar in magnitude to the variance terms. Therefore, we also report the SNP-coheritability between pairs of disorders, which is the covariance between disorders on the liability scale and allows comparison of the shared liability attributable to SNPs on the same scale as the $SNP-h^2$. Here, we apply the univariate and bivariate methods to the five disorders of the PGC: SCZ²¹, BPD²², MDD²³, ASD^{24,25} and ADHD²⁶ analysed in the PGC cross-disorder group association study²⁵, together with additional ADHD data sets²⁷⁻³⁰ (**Table 1**).

RESULTS

SNP-heritabilities for the five disorders

In our linear mixed model we estimate the variance in case-control status explained by SNPs¹⁸ (heritability on the observed scale, CC in **Table 1**). Cases in case-control samples are highly ascertained compared to in the population, and since the different disorder cohorts

have different proportions of cases, the CC estimates are difficult to interpret and compare. For this reason, we report $SNP-h^2$ on the liability scale, in which a linear transformation¹⁸ is applied based on a user-specified estimate of the disorder risk of the study-base population (disorder risk, K). For each disorder we consider three values of K (**Table 1**) and we convert the $SNP-h^2$ to a predicted risk to 1st-degree relatives ($SNP-\lambda_{1st}$) given K . We benchmark the $SNP-\lambda_{1st}$ risk to risk to 1st-degree relatives (λ_{1st}) consistent with estimates of heritabilities reported from family studies given K . Our estimates of $SNP-\lambda_{1st}$ are robust, and of $SNP-h^2$ are reasonably robust, to the likely range of K and show that an important part of the heritabilities or familial risk estimated from family studies are associated with common SNPs. Twice the standard error of estimates approximates the magnitude of parameter that is possible to detect as significantly different from zero given the available sample sizes³¹.

SNP-coheritabilities and SNP-correlations ($SNP-r_g$) between all pairwise combinations of disorders

The relationships between disorders are expressed as SNP-coheritabilities (**Fig. 1**). The $SNP-r_g$ is high for SCZ/BPD 0.68 (s.e. 0.04), moderate for SCZ/MDD 0.43 (0.06), BPD/MDD 0.47 (0.06), ADHD/MDD 0.32 (0.07), low between SCZ/ASD 0.16 (0.06), and non-significant for other pairs of disorders (**Supplementary Table 1**). The $SNP-r_g$ correlation is expected to be equal to the r_g from family studies only if the genetic correlation is the same across the allelic frequency spectrum and if the linkage disequilibrium between genotyped and causal variants is similar for both disorders. The sample size for ASD is the smallest but still can detect correlations of $> |0.18|$ to be different from zero in bivariate analyses with all other disorders.

Our results provide empirical evidence that SCZ, BPD and MDD have a shared genetic etiology. Since some SCZ and BPD cohorts were collected in the same clinical environments,

we investigated possible impact of non-independent collection of SCZ/BPD samples sets but found no significant change in the estimates (**Supplementary Table 2**). The correlation between SCZ and ASD is significant but small (0.16 s.e. 0.06, $p = 0.0071$). In general, our analyses suggest that while common genetic variants contribute to both childhood-onset disorders (ASD, ADHD) and disorders usually diagnosed after childhood (SCZ, BPD, MDD), the sharing of common variants between them is modest.

The pattern of our results (i.e., which pairs of disorders demonstrate genetic overlap) is consistent with the polygenic profile score³² results from the PGC cross-disorder analyses²⁵. The profile score method uses SNP associations from one disorder to construct a linear predictor in another disorder. The profile scores explained small but significant proportions of the variance²⁵, expressed as Nagelkerke's R^2 (maximum of 2.5% between SCZ and BPD). To achieve a high R^2 requires accurate estimation of effect sizes of individual SNPs and depends on the size of the discovery sample. In contrast, our approach uses SNPs to estimate genome-wide similarities between pairs of individuals, resulting in unbiased estimates of the relationships between disorders, with larger sample sizes generating smaller standard errors of the estimates. Our estimates are on the liability scale, allowing direct comparison to genetic parameters estimated in family studies, whereas a genetic interpretation of Nagelkerke's R^2 is less straightforward³³.

Genomic partitioning of SNP-heritabilities and SNP-coheritabilities

The heritabilities explained by SNPs can be partitioned according to SNP annotation by estimation of genetic similarity matrices from multiple, non-overlapping SNP sets. For the five disorders, and the five disorder pairs showing a significant SNP correlation, we partitioned the $SNP-h^2$ and SNP-coheritabilities explained by functional annotation, allocating SNPs to one of three sets: i) in genes preferentially expressed in the central nervous system (CNS+)^{34,35}, ii) in other genes and iii) not in genes, with genes defined with

50kb boundaries from their start/stop positions. The SNPs in the CNS+ gene set represented 0.20 of the total set, both in number and megabases. However, the proportion of the variance explained by SNPs attributable to this SNP set is significantly greater than 0.20 for SCZ (0.30, $p = 7.6 \text{ e-}08$) and BPD (0.32, $p = 5.4\text{e-}06$) and for the SCZ/BPD coheritability (0.37, $p = 8.5\text{e-}08$, **Fig. 2, Supplementary Table 3**). For other disorders or pairs of disorders, the estimates explained by CNS+ SNPs do not differ from chance expectation (**Supplementary Table 3**), although their large standard errors suggest we cannot address this question with precision. For the SCZ/BPD data we also partitioned the heritabilities explained by SNPs by minor allele frequency (MAF) (**Supplementary Table 4**) and by chromosome (**Supplementary Figure 1**). The high standard errors on estimates limits interpretation; but the results are consistent with a polygenic architecture of many common variants of small effect dispersed throughout the genome. The MAF partitioning suggests that an important part of the variance explained by SNPs is attributable to common causal variants (this was investigated in detail for SCZ³⁵), but the low contribution to the total variance explained from SNPs with $\text{MAF} < 0.1$ reflects, at least in part, under-representation of SNPs with low MAF in the analysis (minimum $\text{MAF} = 0.01$) relative to those present in the genome.

Within disorder heterogeneity

In order to benchmark the estimates of genetic sharing across disorders, we estimated sharing between data sub-sets of the same disorder. We split the data for each disorder into 2 or 3 independent sets and estimated the $\text{SNP-}h^2$ from each subset, and the SNP-coheritability between each pair of subsets within a disorder (**Fig. 3a, Supplementary Table 5**). The estimates of $\text{SNP-}h^2$ from the data sub-sets are typically higher than the $\text{SNP-}h^2$ from the combined sample; we note that published estimates from individual cohorts of BPD¹⁸, MDD³⁶ and ASD³⁷ were also higher. Since both traits in these data sub-set bivariate analyses are from the same disorder, the SNP-coheritability is also an estimate of the SNP-

h^2 for the disorder, but these are generally lower than the estimates of SNP-heritability from individual data sub-sets. These results generate SNP-correlations that are less than one, and sometimes significantly so (**Supplementary Table 5**). The SCZ/BPD SNP correlation (0.68 s.e. 0.04) is of comparable magnitude as the SNP-correlations between BPD data sets (0.63 s.e. 0.11, 0.88 s.e. 0.09 and 0.55 s.e. 0.10 ; **Fig 3a,b** for SNP coheritabilities), adding further weight to the conclusion that SCZ and BPD may be part of the same etiological spectrum.

The estimates of heritability from both univariate (**Fig. 3a** red/pink bars) and bivariate analyses (**Fig. 3a** blue bars) are more heterogeneous for BPD, MDD and ADHD than for SCZ and ASD. Several reasons could explain why SNP-heritabilities from univariate analyses of a single data set could generate higher estimates than from bivariate analyses of independent data sets³⁵, including loss of real signal or dilution of artefacts. Loss of real signal may occur because individual cohorts are more homogeneous, both phenotypically (e.g., use of the same assessment protocols), and genetically (e.g. because linkage disequilibrium (LD) between causal variants and analyzed SNPs might be higher within than between cohorts). On the other hand, artefacts could generate consistent differences in case vs control genotypes within case-control data sets. In the derivation of our methodology¹⁸, we emphasised that any factors making SNP genotypes of cases more similar to other cases, and controls more similar to controls, will produce SNP-heritability. The fitting as covariates of principal components derived from the SNP data corrects both for population stratification and for genotyping artefacts, but residual population stratification³⁸ could remain, although this bias should be small^{38,39}. Partitioning SNP-heritability by chromosome in analyses where each chromosome is fitted individually compared to analyses where all chromosomes are fitted jointly is an empirical strategy to assess residual stratification^{35,40} and we find no such evidence here (**Supplementary Figure 1**). Stringent QC helps (as applied here) to remove artefacts, but artefactual differences between cases and controls may remain, particularly

for data sets in which cases and controls have been genotyped independently⁴¹. As more data sets accumulate, the contributions from artefacts are diluted since the random directional effects of artefacts (including population stratification) are not consistent across data sets. For this reason, significant SNP-coheritabilities are unlikely to reflect artefacts and provide a lower bound on SNP-heritability.

Pseudo-controls

One strategy adopted in GWAS to guard against artefacts of population stratification is to genotype trio samples (cases and their parents) and then analyse the data as a case-control sample with controls generated as genomic complements of the cases (i.e. “pseudo-controls”). The ADHD subset 1 and most of the ASD sample are comprised of case-pseudo control samples and, consistent with limiting the impact of artefacts from population stratification or genotyping, it is noted that the lowest SNP-heritability of the 5 psychiatric disorders is for ASD and that the estimate of SNP-heritability is lower for ADHD subset 1 than for ADHD subset 2. However, under a polygenic model, assortative mating⁴² or preferential ascertainment of multiplex families could diminish the expected mean difference in liability between pseudo-controls and cases³⁷, which would result in an underestimation of SNP-heritability from case/pseudo-control compared to case/control analyses and also non-zero estimates of SNP-heritability from pseudo-control/control analyses as shown in analysis of ASD data³⁷.

Negative control – SNP-coheritabilities with Crohn’s Disease

As a negative control analysis, we conducted bivariate analyses between each of the PGC data sets with Crohn’s Disease (CD) from the International IBD Genetics Consortium (IIBDGC)⁴³. While onset of MDD is not uncommon after diagnosis with CD⁴⁴, and while gastrointestinal pathology is commonly comorbid with ASD⁴⁵, there is no strong evidence of

a familial relationship between psychiatric disorders and CD. Despite a substantial SNP- h^2 for CD (0.19 s.e. 0.01), none of the SNP-coheritabilities with the psychiatric disorders differed significantly from zero (**Fig. 3c, Supplementary Table 6, Supplementary Note**). Lastly, the genomic partitioning by annotation of variance in CD explained by SNPs showed, as expected, no excess of variance attributable to SNPs in the CNS+ gene set (**Fig. 2**). Our results provide no evidence for common genetic pleiotropy between CD and ASD consistent with a non-genetic e.g. microbial⁴⁷ explanation for the comorbid gastrointestinal symptoms in ASD.

Potential impact of misclassification of disorders

Misclassification between disorders could inflate estimates of genetic correlation/coheritability⁴⁸. Indeed, some level of misclassification between psychiatric disorders is expected. For example, longitudinal studies^{49,50} of first admissions with psychosis based on research interviews showed that with long term follow-up ~15% of subjects initially diagnosed with bipolar disorder were re-diagnosed with schizophrenia while ~4% of schizophrenia diagnoses were re-classified as bipolar disorder. Cases selected for GWAS contributing to PGC to date are more likely to have achieved a stable diagnosis compared to first admission cases. However, assuming these levels of misclassification, the genetic correlation between BPD and SCZ of “true” diagnoses is still high, estimated⁴⁸ to be 0.55. Likewise, since a modest proportion of cases diagnosed with MDD followed over time ultimately meet criteria for BPD⁵¹ our estimated genetic correlation between these two disorders may be modestly inflated by misclassification. On the other hand, if moderate to high genetic correlations between the major adult disorders are true, then overlapping symptoms and misdiagnosis between disorders might be expected. The SNP- r_g between SCZ and MDD also is unlikely to reflect misdiagnosis since misclassification between these disorders is rare⁵¹. Excluding the five of the 18 PGC-SCZ cohorts containing schizoaffective

disorder cases²¹ (**Supplementary Table 7**) or MDD cohorts ascertained from community rather than clinical settings (**Supplementary Table 8**) had little impact on the SNP-rg estimates .

DISCUSSION

Our results show direct, empirical, quantified, molecular evidence for an important genetic contribution to the five major psychiatric disorders. The *SNP- h^2* estimates for each disorder: SCZ 0.21 (s.e. 0.02), BPD 0.25 (s.e. 0.01), MDD 0.21 (s.e. 0.01), ASD 0.14 (s.e. 0.02), ADHD 0.32 (s.e. 0.02) are considerably less than the heritabilities estimated from family studies (see **Table 1**). Yet they show that common SNPs make an important contribution to the overall variance, implying that additional individual common SNP associations can be discovered as sample size increases⁵². *SNP- h^2* are a lower bound of narrow sense heritability because they exclude contributions from some causal variants (mostly rare variants) not associated with common SNPs. Although the SNP-heritability estimate is similar for MDD as for other disorders, much larger sample sizes will be needed because the high disorder risk implies lower power for the same sample size⁵³. The *SNP- h^2* are all lower than those reported for height (0.45 s.e. 0.03)⁴⁰ but the estimates are in the same ball-park to those reported for other complex traits and diseases using the same QC pipeline, such as BMI (0.17 s.e. 0.03)⁴⁰, Alzheimer's Disease (0.24 s.e.0.03), multiple sclerosis (0.30 s.e.0.03) and endometriosis (0.26 s.e.0.04)⁴¹.

Our results show molecular evidence for the sharing of genetic risk factors across key psychiatric disorders. Traditionally, quantification of the genetic relationship between disorders has been thwarted by the need for cohorts of families or twins assessed for multiple disorders. Problems of achieving genetically informative samples of sufficient size and without associated ascertainment biases for the rarer psychiatric disorders have meant that few studies have produced meaningful estimates of genetic correlations. Importantly,

our estimates of heritability and genetic correlation are made using very distant genetic relationships between individuals, both within and between disorders, so that shared environmental factors are unlikely to contaminate our estimates. Likewise, our estimates are unlikely to be confounded by non-additive genetic effects, since the coefficients of non-additive genetic variance between very distant relatives are negligible⁵⁴.

The estimates of SNP-genetic correlation (SNP- r_g) between disorders reflect genome-wide pleiotropy of variants tagged by common SNPs and whether these are the same as correlations across the allelic frequency spectrum may differ between disorder pairs. For example, a high SNP- r_g but a low genetic correlation estimated from family studies (r_g) could reflect that the same common variants contribute to the genetic susceptibility of both disorders, while the diagnostic-specific variants are less common variants. For this reason, the comparison of SNP- r_g with r_g estimated from family studies is not straightforward. Nonetheless we benchmark our estimates in this way, calculating the increased risk of disorder B in first-degree relatives of probands with disorder A ($\lambda_{A,B}$) from the SNP- r_g to allow comparison with literature values (**Supplementary Table 1**). A meta-analysis⁵⁵ reported the increased risk of BPD in first-degree relatives of SCZ probands compared to first-degree relatives of control probands ($\lambda_{SCZ,BPD}$) to be 2.1, which implies a maximum genetic correlation between them of 0.3 (assuming that the disorder risks for SCZ and BPD are both 1%, and their heritabilities are 81% and 75%, **Table 1**). However, a large-scale Swedish family and adoption study⁵⁶ estimated the genetic correlation between SCZ and BPD to be +0.60, similar to that found here. Profiling scoring analyses using genome-wide SNPs³² was the first to demonstrate clearly a genetic relationship based on molecular data, but quantification as a genetic correlation was not reported. The evidence of shared genetic risk factors for SCZ and BPD was strengthened by our analyses of the CNS+ gene set where we saw a clear enrichment in variants shared by these two disorders.

Our finding of a substantial SNP- r_g of +0.43 between SCZ and MDD is intriguing and contrary to conventional wisdom about the independence of familial risk for these disorders. However, since MDD is common, even a high genetic correlation implies only modest incremental risk. Assuming that the disorder risks and heritabilities for SCZ and MDD in Table 1, then a the genetic correlation between them of 0.43 predicts an increased risk of MDD in first-degree relatives of SCZ probands compared to first-degree relatives of control probands ($\lambda_{\text{rel}} = 1.6$). In fact, meta-analysis of five studies interview-based research studies of families are broadly consistent with our results ($\lambda_{\text{rel}} = 1.5$, 95% CI 1.2-1.8, **Supplementary Table 9**), suggesting that familial coaggregation of MDD and SCZ reflects genetic effects rather than a consequence of living in a family environment that includes a severely ill family member. If replicated by future work, our empirical molecular genetic evidence of a partly shared genetic etiology for SCZ and MDD has important nosological and research implications, placing MDD as part of a broad psychiatric genetic spectrum. A shared genetic etiology between BPD and MDD has been shown in family studies^{2,3} but the SNP- r_g of 0.47 is lower than the estimate of 0.65 from a twin study⁵⁷.

Our results show a small but significant SNP- r_g between SCZ and ASD. A lower genetic correlation between SCZ and ASD than between SCZ and BPD is consistent with the Swedish national epidemiological studies which reported higher odds ratios in siblings between SCZ and BPD⁵⁶ than between SCZ and ASD⁹. These results imply a modest overlap of common genetic etiologic processes in these two disorders consistent with emerging evidence from discovery of copy number variants where both shared variants (e.g. 15q13.3, 1q2.1 and 17q12 deletions^{58,59}) and same gene but different variants (deletions associated with schizophrenia and duplications associated with autism, and vice versa¹⁰) have been reported. The small ASD sample size thwarted attempts of further explorative partitioning of the SNP coheritability between SCZ and ASD.

The lack of overlap between ADHD and ASD is surprising and not consistent with family and data linkage studies, which indicate that the two disorders share genetic risk factors^{5,6,60,61}. Some rare copy number variants are seen in both disorders¹⁶. As noted above, the use of pseudo-controls for many of the ASD and ADHD cohorts may impact on all results for these disorders. Ideally we would investigate the impact of pseudo-controls given the hierarchical diagnostic system (autism, but not autism spectrum is an exclusion criterion for most ADHD data sets) on estimates of the SNP-coheritability, but the small ASD sample size prohibits such analyses. We also found no overlap between ADHD and bipolar disorder despite meta-analytic support for an increased risk for ADHD in relatives of BPD I (a subtype of BPD with more extreme manic symptoms than the other major BPD subtype) patients and an increased risk for BPD I in relatives of ADHD patients¹². This could mean that the familial link between the two disorders is mediated by environmental risk factors or that the shared genetic factors are not part of the common allelic spectrum. Alternatively, the etiologic link between ADHD and BPD might be limited to BPD I or early onset BPD¹² which therefore is difficult for us to detect. Our finding of genetic overlap between ADHD and MDD is consistent with evidence from studies showing increased rates of ADHD in families of depressed probands and increased rates of depression in families of ADHD probands^{12,13}.

Our results should be interpreted in the context of four potentially important methodological limitations. First, any artefacts, that make SNP genotypes more similar between cases than between cases vs. controls could inflate estimates of SNP-heritability¹⁸, but to a much lesser extent SNP-coheritability. Second, the sample sizes varied considerably across the five disorders. Although the $SNP-h^2$ are expected to be unbiased, estimates from smaller samples are accompanied by larger standard errors, blurring their interpretation. Third, while applying similar diagnostic criteria, the clinical methods of ascertainment and the specific study protocols, including which specific interview instruments were employed, varied across sites. We cannot now determine the degree to which our results might have

been influenced by the between-site differences in the kinds of patients seen or in their assessments. Fourth, by combining samples from geographical regions, contributions from less common associated variants specific to populations are diluted compared to what could be achieved if the same sample size had been ascertained from a single homogeneous population.

In summary, we report SNP-heritabilities that are significantly greater than zero for all five disorders studied. We have used the largest psychiatric GWAS data sets currently available and our results provide important pointers for future studies. Our results demonstrate that the dearth of significant associations from psychiatric GWAS to date, particularly for MDD, ASD and ADHD, reflects lack of power to detect common associated variants of small effect rather than absence of such variants. Hence as sample sizes increase the success afforded to other complex genetic diseases⁵² in progressing understanding of their etiology is achievable for psychiatric disorders, as already being shown for SCZ⁶². We also provide evidence for a substantial sharing of the genetic risk variants “tagged” by these SNPs for SCZ/BPD, BPD/MDD, SCZ/MDD, ADHD/MDD and, to a lesser extent, SCZ/ASD. Our results will likely contribute to efforts now underway to base psychiatric nosology on a firmer empirical footing. Furthermore, they will encourage investigations into shared pathophysiologies across disorders including potential clarification of common therapeutic mechanisms.

Note: Supplementary information is available on the Nature Genetics website.

Acknowledgements

This research was directly supported by the Australian Research Council (FT0991360, DE130100614) and the Australian National Health and Medical Research Council (613608, 1011506, 1047956). The PGC-CDG is supported by NIMH grant U01 MH085520. Statistical analyses were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>) which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003 PI Posthuma) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam. Numerous (>100) grants from government agencies along with substantial private and foundation support world-wide enabled the phenotype and genotype data collection without which this research would be not be possible; the grants are listed in the primary PGC publications or in the **Supplementary Note**.

Author Contributions

Project Conception: KSK, NRW, JWS. **Analysis:** SHL, NRW. **Writing of manuscript:** NRW, SHL, KSK, SVF. **QC of PGC data:** S Ripke, BMN. **Revisions to the manuscript:** SMP, JWS, RHP, BJM, PFS, AT, CO'D, MJD, RDO, JB. **Statistical advice:** MEG, JSW. **Data access:** DP. **PGC-CDG Working Group Chairs:** MJD (Analysis), SVF (ADHD), MJD, BD (co-chairs ASD), JK, P Sklar (co-chairs BPD), PFS (MDD), MCO'D (SCZ). **Collection, genotyping and analysis of Psychiatric Genomics Consortium Working Groups:** **PGC-ADHD Working Group:** BMN, SVF, AT, RA, PA, TB, M Bayés, JB, JKB, MC, BC, JC, AED, RPE, JE, BF, CMF, L Kent, JK, K-PL, SKL, JMcG, SEM, JMS, AM, SFN, RDO, JAR-Q, A Reif, M Ribasés, HR, A Rothenberger, JAS, RS, SL Smalley, EJSS-B, H-CS, AAT, NW. **PGC-ASD Working Group:** RA, DEA, AJB, AB, CB, JD Buxbaum, A Chakravarti, EHC, HC, MLC, GD, ED, SE, EF, CMF, L Gallagher, DHG, M Gill, DEG, JLH, HH, JH, VH, SMK, L Klei, DH Ledbetter, C Lord, JKL, EM, SMM, CLM, WMMcM, APM, DM-D-L, EMM, M Murtha, GO, AP, JRP, ADP, MAP-V, J Piven, FP, K Rehnström, K Roeder, GR, SJS, S Cichon, GDS, SWS, M State, J Sutcliffe, P Szatmari, AMV, VJV, CAW, THW, EMW, AJW, TWY, BD, MJD. **PGC-BPD Working Group:** SMP, DA, HA, OAA, AA, LB, JAB, JD Barchas, TBB, NB, M Bauer, FB, SEB, WB, DHRB, CSB, M Boehnke, GB, R Breuer, WEB, WFB, S Caesar, K Chambert, S Cichon, DAC, A Corvin, WHC, DWC, RD, F Degenhardt, S Djurovic, F Dudbridge, HJE, BE, AEF, INF, M Flickinger, TF, JF, CF, LF, ESG, M Gill, KG-S, EKG, TAG, DG, WG, HG, MLH, M Hautzinger, S Herms, M Hipolito, PAH, CMH, SJ, EGJ, IJ, LJ, R Kandaswamy, JLK, GKK, DLK, PK, M Landén, NL, M Lathrop, J Lawrence, WBL, M Leboyer, PHL, J Li, PL, D-YL, C Liu, FWL, SL, PB Mahon, WM, NGM, M Mattheisen, KM, M Mattingsdal, KAMcG, PMcG, MGMT, AMcI, RMcK, AWM, FJMcM, AMcQ, SM, IM, FM, GWM, JLM, GM, DWM, V Moskvina, P Muglia, TWM, WJM, BM-M, RMM, CMN, IN, VN, MMN, JIN, EAN, CO'D, UO, MJO, BSP, JBP, PP, EMQ, S Raychaudhuri, A Reif, JPR, M Rietschel, D Ruderfer, M Schalling, AFS, WAS, NJS, TGS, J Schumacher, MS, ES, LJS, PDS, ENS, DStC, M Steffens, JSS, J Strohmaier, S Szelinger, RCT, FT, JT, JBV, SJW, TFW, SHW, WX, AHY, PPZ, PZ, S Zöllner, JRK, P Sklar, MJD, MCO'D, NC. **PGC-MDD Working Group:** MRB, TB, EBB, DHRB, DIB, GB, R Breuer, S Cichon, WHC, IWC, D Czamara, EJCGD, F Degenhardt, AEF, JF, SDG, M Gross, SPH, ACH, AKH, S Herms, IBH, S Cichon, FH, WJH, J-JH, MI, IJ, LJ, TJ-Y, JAK, MAK, A Korszun, WBL, DFL, CML, D-YL, SL, DJMacI, PAFM, WM, NGM, M Mattheisen, PJMcG, PMcG, AMcI, AWM, CMM, LM, GWM, P Muglia, BM-M, WAN, MMN, DRN, BWP, MLP, JBP, M Rietschel, WAS, TGS, J Shi, SIS, SL Slager, JHS, M Steffens, FT, JT, MU, EJvdO, GV, MMW, GW, FGZ, PFS, NRW. **PGC-SCZ Working Group:** S Ripke, BMN, SMP, BJM, IA, FA, OAA, MHA, NB, DWB, DHRB, R Bruggeman, NGB, WFB, WC, RMC, K Choudhury, S Cichon, CRC, A Corvin, D Curtis, S Datta, S Djurovic, GJD, JD, F Dudbridge, AF, RF, NBF, M Friedl, PVG, L Georgieva, IG, M Gill, HG, LdH, MLH, TFH, AMH, PAH, CMH, AI, A Kahler, RSK, MCK, EK, YK, GKK, BK, L Krabbendam, R Krasucki, J Lawrence, PHL, TL, DFL, JAL, D-YL, DH Linszen, PKEM, WM, AKM, M Mattheisen, M Mattingsdal, SMcC, AMcI, AMcQ, HM, IM, V Milanova, DWM, V Moskvina, IM-G, MMN, CO'D, AO, LO, RAO, MJO, CNP, MTP, BSP, J Pimm, DP, VP, DJQ, HBR, M Rietschel, LR, D Ruderfer, D Rujescu, ARS, TGS, J Shi, JMS, DStC, TSS, ST, JV, PMV, TW, DW, S Zammit, P Sklar, MJD, MCO'D, NC, PFS, KSK. **PGC-CDG Working Group:** SHL, S Ripke, BMN, SMP, RHP, AT, AF, MCN, JIN, BWP, M Rietschel, S Cichon, TGS, NC, PFS, JWS, KSK, NRW. **PGC-Analysis Working Group:** SHL, S Ripke, BMN, SMP, VA, EMB, PHL, SEM, MCN, DP, MJD, NRW

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Figure 1. Evidence for genome-wide pleiotropy between psychiatric disorders. a. Proportion of variance in liability (SNP-heritability), and proportion of covariance in liability between disorder (SNP-coheritability) for 5 major psychiatric disorders. 95% error bars are estimate ± 1.96 standard error.

Figure 2 Genomic partitioning of SNP-heritability/SNP-coheritability by annotation. Proportion of SNPs attributable to genes in CNS+ set (red bar), proportion of SNP-heritability explained by SNPs attributed to SNPs in CNS+ set (dark green bar), proportion of SNP-coheritability attributed to SNPs in CNS+ set (light green bar), proportion of SNP-heritability for Crohn's Disease attributed to SNPs in CNS+ set (orange bar). 95% error bars are estimate ± 1.96 standard error. *** $p < 10^{-5}$ from test that proportion of heritability explained by SNPs = proportion of SNPs.

Figure 3 SNP-heritabilities and coheritabilities. a) For each disorder the SNP-heritabilities are estimated from univariate analyses of the full data set (dark green bars) or from subsets (red/pink bars). They are also estimated from bivariate analyses in which different subsets of the same disorder comprise the two traits (blue bars). Test of heterogeneity of estimates, p-value for Cochrane's Q, SCZ: 0.3, BPD: 1×10^{-6} , MDD: 4×10^{-3} , ADHD: 9×10^{-6} , ASD: 0.99 Higgins' I2, SCZ: 21%, BPD: 86%, MDD: 71% ADHD: 91% ASD:0 b) For comparison the coheritabilities using the full data sets from Figure 1. c) As a negative control, estimates of coheritabilities with Crohn's Disease (CD), a disease not expected to be genetically related to psychiatric disorders. 95% error bars are estimate ± 1.96 standard error.

Table 1. Univariate analyses: sample description, SNP-heritabilities and recurrence risk to first-degree relatives

	SCZ	BPD	MDD	ASD	ADHD
SNPs(imputed)	915354	995971	962093	982100	917066
Cases	9087	6704	9041	3303	4163
Controls	12171	9031	9381	3428 ^a	12040 ^a
N cohorts	17	11	9	8	8
Primary Reference	21	22	23	24,25	26-30
CC (s.e.)	0.41 (0.015)	0.44 (0.021)	0.18 (0.017)	0.31 (0.046)	0.25 (0.020)
Disorder risk for the study-base population (disorder risk, K) used in Figures and Supplementary Tables					
K	0.01	0.01	0.15	0.01	0.05
SNP- h^2 (s.e.)	0.23 (0.008)	0.25 (0.012)	0.21 (0.021)	0.17 (0.023)	0.28 (0.023)
$\lambda_{1st-SNP}$ (s.e)	2.10 (0.05)	2.23 (0.08)	1.27 (0.03)	1.75 (0.14)	1.71 (0.07)
λ_{1st}	8.8	9.6	1.5	8.7	3.5
Lower bound for disorder risk (K)					
K	0.004	0.007	0.1	0.001	0.03
SNP- h^2 (s.e.)	0.19 (0.007)	0.23 (0.010)	0.19 (0.020)	0.11 (0.017)	0.24 (0.020)
$\lambda_{1st-SNP}$ (s.e)	2.14 (0.06)	2.25 (0.08)	1.31 (0.03)	1.79 (0.15)	1.77 (0.07)
λ_{1st}	14.4	11.7	1.7	29.4	4.5
Upper bound for disorder risk (K)					
K	0.012	0.015	0.2	0.015	0.08
SNP- h^2 (s.e.)	0.24 (0.009)	0.27 (0.013)	0.23 (0.023)	0.19 (0.028)	0.32 (0.026)
$\lambda_{1st-SNP}$ (s.e)	2.10 (0.05)	2.20 (0.07)	1.24 (0.02)	1.74 (0.13)	1.65 (0.06)
λ_{1st}	8.0	7.7	1.4	7.0	2.8
<i>Heritability estimated from twin/family studies</i> ⁶³					
h^2	0.81	0.75	0.37	0.80	0.75

SCZ: schizophrenia, BPD: bipolar disorder, MDD: major depressive disorder, ASD: autism spectrum disorders, ADHD: attention deficit hyperactivity disorder. CC=SNP-heritability estimated on case-control scale. SNP- h^2 SNP-heritability on liability scale given assumed K . All estimates of SNP- h^2 are highly significantly different from zero. $\lambda_{1st-SNP}$ recurrence risk to first degree relatives calculated from SNP- h^2 liability and K . λ_{1st} recurrence risk to first degree relatives calculated from h^2 from twin/family studies and K . a) some cohorts include cases and pseudo-controls where pseudo-controls are the genomic complements of the cases derived from genotyping of proband-parent trios.

Methods

Data & quality control (QC)

A summary of the data available for analysis is listed in **Table 1** and comprise data used in the PGC-Cross Disorder Group analysis²⁵ together with newly available ADHD samples²⁷⁻³⁰. Data upload to the PGC central server follows strict guidelines to ensure local ethics committee approval for all contributed data (<https://pgc.unc.edu/>). Data from all study cohorts were processed through the stringent PGC pipeline²⁵. Imputation of autosomal SNPs used the CEU+TSI Hapmap Phase 3 data as the reference panel²¹. For each analysis (univariate or bivariate), we retained only SNPs that had minor allele frequency > 0.01 and imputation $R^2 > 0.6$ in all contributing cohort sub-samples (imputation cohorts). Different QC strategies were investigated in detail for the raw and PGC imputed genotyped data of the International Schizophrenia Consortium, a subset of the PGC SCZ sample³⁵. The CD samples from the International IBD Genetics Consortium (IIBDGC)⁴³ were processed through the same QC and imputation pipeline as the PGC data, generating a data set of 5054 cases and 11496 controls from 6 imputation cohorts.

In each analysis, individuals were excluded to ensure that all cases and controls were completely unrelated in the classical sense, so that no pairs of individuals had a genome-wide similarity relationship greater than 0.05 (equivalent to about second-cousins). This procedure removed ancestry outliers (over and above those already removed in the PGC QC pipeline, **Supplementary Figures 2-5**) and ensured that overlapping control sets were allocated randomly between disorders in the bivariate analyses. Exact numbers of cases and controls used in each analysis are listed in **Supplementary Tables 1-8**.

Linear mixed model for estimation of SNP-heritability and SNP-coheritability

We use the methods presented in Lee *et al.*^{18,35} Briefly, we estimate the variance in case-control status explained by all SNPs using a linear mixed model,

$$\mathbf{y} = \mathbf{X}\boldsymbol{\beta} + \mathbf{g} + \mathbf{e} \quad (1)$$

where \mathbf{y} is a vector of case (=1) or control (=0) status (the “observed scale”), $\boldsymbol{\beta}$ is a vector for fixed effects of the overall mean (intercept), sex, sample cohort and 20 ancestry principal components, \mathbf{g} is the vector of random additive genetic effects based on aggregate SNP information, and \mathbf{e} is a vector of random error effects. \mathbf{X} is an incidence matrix for the fixed effects relating these effects to individuals. The variance structure of phenotypic observations is $V(\mathbf{y}) = \mathbf{V} = \mathbf{A}\sigma_g^2 + \mathbf{I}\sigma_e^2$, where σ_g^2 is additive genetic variance tagged by the SNPs, σ_e^2 is error variance, \mathbf{A} is the realized similarity relationship matrix estimated from SNP data¹⁹ and \mathbf{I} is an identity matrix. All variances are estimated on the observed case-control scale and are transformed to the liability scale, which requires specification of the disorder risk, K , to estimate SNP- h^2 . Risk to first-degree relatives is calculated from K and SNP- h^2 based on the liability threshold model⁶⁴.

The bivariate analyses use a bivariate extension of equation (1)²⁰. The two traits are measured on different individuals, but the equations are related through the genome-wide similarities estimated from SNPs. Genetic and residual variances for the traits are estimated as well as the genetic covariance σ_{g12} . The genetic correlation coefficient (r_g) is

$\sigma_{g12}/(\sigma_{g1}\sigma_{g2})$ and is approximately the same on the observed case-control scale as on the liability scale²⁰ so does not depend on specifications of K . The covariance, σ_{g12} , can be transformed to the liability scale accounting for assumed disorder risks and proportions of cases and controls in the samples of each disorder²⁰ and it equals the coheritability⁵⁴, $r_g h_1 h_2$. We used the approximated chi-square test statistic (estimate/s.e.)² to test if estimates were significantly different from zero. We checked that this simple approximation agreed well with the more formal and computer-intensive likelihood ratio test for several examples.

Heterogeneity of SNP-heritabilities was tested using Cochran's⁶⁵ Q and Higgins'⁶⁶ I^2 , acknowledging potential non-independence of the 6 estimates (3 subsets plus 3 subset pairs).

Disorder risk for the study-base population (disorder risk, K)

The estimates of SNP- h^2 and SNP-coheritability from the linear model are on the case-control scale and so depend partly on the proportion of cases and controls in the sample. The transformation to the liability scale allows benchmarking of SNP- h^2 to estimates of heritability from family studies, and the transformation accounts for the proportion of cases in the sample and depends on the assumed disorder risk (K). The appropriate choice of K depends on the definitions of both the phenotype (including ascertainment strategy) and the population, which may differ between cohorts. We consider lower and upper bounds for K in Table 1 to cover the range of possible values. $SNP-r_g$ estimates are independent of scale and hence are not dependent on the choice of K .

Genome partitioning linear mixed model

We partitioned the variance explained by the SNPs in several ways. For example, for the

univariate linear model $\mathbf{y} = \mathbf{X} + \sum_{t=1}^n \mathbf{g}_t + \mathbf{e}$ with $V(\mathbf{y}) = \mathbf{V} = \sum_{t=1}^n \mathbf{A}_t \frac{2}{g_{tc}} + \mathbf{I} \frac{2}{e}$

where n is the number of subsets from any non-overlapping partitioning of SNPs; $n = 22$ for the joint analysis by chromosome, $n = 5$ for the analysis by MAF bin and $n = 3$ for the analysis of SNP by gene annotation in which SNPs were classed as “CNS+ genes” (2,725 genes representing 547 Mb), SNPs in “other genes” (14,804 genes representing 1,069 Mb) and the remaining SNPs “not in genes”. Gene boundaries as ± 50 kb from 3' and 5' UTRs of each gene and the CNS+ genes were the four sets identified by Raychaudhuri *et al.*³⁴ (one set comprised genes expressed preferentially in the brain compared to other tissues and the other three sets comprised genes annotated to be involved in neuronal activity, learning and synapses). The CNS+ set was found to explain more of the SNP-heritability than expected by

chance for schizophrenia³⁵. All methods have been implemented into the freely available GCTA software⁶⁷.

References

References

- 1 Kendler, K. S. & Eaves, L. J. Psychiatric Genetics (Review of Psychiatry). *Am. Psychiatric Assoc.* (2005).
- 2 Tsuang, M. & Faraone, S. *The genetics of mood disorders.* (Johns Hopkins University Press, 1990).
- 3 Smoller, J. W. & Finn, C. T. Family, twin, and adoption studies of bipolar disorder. *Am. J. Med. Genet. C Semin. Med. Genet.* **123**, 48-58 (2003).
- 4 Ronald, A., Simonoff, E., Kuntsi, J., Asherson, P. & Plomin, R. Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. *J. Child Psychol. Psychiatry Allied Disciplines* **49**, 535-542 (2008).
- 5 Rommelse, N. N., Franke, B., Geurts, H. M., Hartman, C. A. & Buitelaar, J. K. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. *Europ. Child Adol. Psychiatry* **19**, 281-295 (2010).
- 6 Lichtenstein, P., Carlstrom, E., Rastam, M., Gillberg, C. & Anckarsater, H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. *Am. J. Psychiatry* **167**, 1357-1363, doi:10.1176/appi.ajp.2010.10020223 (2010).
- 7 Rapoport, J., Chavez, A., Greenstein, D., Addington, A. & Gogtay, N. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. *J. Am. Acad. Child Adol. Psychiatry* **48**, 10-18 (2009).
- 8 King, B. H. & Lord, C. Is schizophrenia on the autism spectrum? *Brain. Res.* **1380**, 34-41 (2011).
- 9 Sullivan, P. F. *et al.* Family history of schizophrenia and bipolar disorder as risk factors for autism *Archives of General Psychiatry* **69**, 1099-1103 (2012).
- 10 Crespi, B., Stead, P. & Elliot, M. Comparative genomics of autism and schizophrenia. *P Natl Acad Sci USA* **107**, 1736-1741 (2010).
- 11 Mortensen, P. B., Pedersen, M. G. & Pedersen, C. B. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? *Psychol Med* **40**, 201-210, doi:10.1017/S0033291709990419 (2010).
- 12 Faraone, S. V., Biederman, J. & Wozniak, J. Examining the Comorbidity Between Attention Deficit Hyperactivity Disorder and Bipolar Disorder: A Meta-Analysis of Family-Genetic Studies. *American Journal of Psychiatry* **169**, 1256-1266 (2012).
- 13 Cole, J., Ball, H. A., Martin, N. C., Scourfield, J. & McGuffin, P. Genetic overlap between measures of hyperactivity/inattention and mood in children and adolescents. *J. Am. Acad. Child Adol. Psychiatry* **48**, 1094-1101 (2009).
- 14 Craddock, N., O'Donovan, M. C. & Owen, M. J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. *Schizophr. Bull.* **32**, 9-16, doi:10.1093/schbul/sbj033 (2006).
- 15 Green, E. K. *et al.* The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. *Mol. Psychiatry* **15**, 1016-1022, doi:10.1038/mp.2009.49 (2010).
- 16 Williams, N. M. *et al.* Genome-wide analysis of copy number variants in attention deficit/hyperactivity disorder confirms the role of rare variants and implicates duplications at 15q13.3 *Am. J. Psychiatry* **169**, 195-204 (2012).
- 17 Manolio, T. A. Genomewide association studies and assessment of the risk of disease. *N. Engl. J. Med.* **363**, 166-176, doi:10.1056/NEJMra0905980 (2010).
- 18 Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing heritability for disease from genome-wide association studies. *Am. J. Hum. Genet.* **88**, 294-305 (2011).

- 19 Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.* **42**, 565-569 (2010).
- 20 Lee, S. H., Yang, J., Goddard, M. E., Visscher, P. M. & Wray, N. R. Estimation of pleiotropy between complex diseases using SNP-derived genomic relationships and restricted maximum likelihood. *Bioinformatics* **28**, 2540-2542 (2012).
- 21 Ripke, S. *et al.* Genome-wide association study identifies five new schizophrenia loci. *Nat. Genet.* **43**, 969-976 (2011).
- 22 Sklar, P. *et al.* Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat. Genet.* **43**, 977-983 (2011).
- 23 Psychiatric GWAS Consortium Major Depressive Disorder. A mega-analysis of genome-wide association studies for major depressive disorder. *Mol. Psychiatry* (2012).
- 24 Anney, R. *et al.* Individual common variants exert weak effects on the risk for autism spectrum disorders. *Hum. Mol. Genet.*, doi:10.1093/hmg/dds301 (2012).
- 25 Cross-Disorder Group of the Psychiatric GWAS Consortium. Genome-wide analysis identifies loci with shared effects on five major psychiatric disorders. *Lancet In press* (2012).
- 26 Neale, B. M. *et al.* Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. *J. Am. Acad. Child Adolesc. Psychiatry* **49**, 884-897 (2010).
- 27 Stergiakouli, E. *et al.* Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. *Am. J. Psychiatry* **169**, 186-194 (2012).
- 28 Lionel, A. C. *et al.* Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. *Sci. Transl. Med.* **3**, 95ra75 (2011).
- 29 Hinney, A. *et al.* Genome-wide association study in German patients with attention deficit/hyperactivity disorder. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **156B**, 888-897 (2011).
- 30 Ribases, M. *et al.* Exploration of 19 serotonergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. *Molecular psychiatry* **14**, 71-85, doi:10.1038/sj.mp.4002100 (2009).
- 31 Lynch, M. & Walsh, B. *Genetics and Analysis of Quantitative Traits*. (Sinauer Associates, 1998).
- 32 Purcell, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748-752, doi:10.1038/nature08185 (2009).
- 33 Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214-224 (2012).
- 34 Raychaudhuri, S. *et al.* Accurately Assessing the Risk of Schizophrenia Conferred by Rare Copy-Number Variation Affecting Genes with Brain Function. *Plos Genetics* **6**, e1001097. (2010).
- 35 Lee, S. H. *et al.* Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. *Nat. Genet.* **44**, 247-250 (2012).
- 36 Lubke, G. H. *et al.* Estimating the Genetic Variance of Major Depressive Disorder Due to All Single Nucleotide Polymorphisms. *Biol. Psychiatry* (2012).
- 37 Klei, L. *et al.* Common genetic variants, acting additively, are a major source of risk of autism. *Molecular autism* **Epub ahead of print** (2012).
- 38 Browning, S. R. & Browning, B. L. Population structure can inflate SNP-based heritability estimates. *Am. J. Hum. Genet* **89**, 191-193; author reply 193-195 (2011).
- 39 Goddard, M. E., Lee, S. H., Yang, J., Wray, N. R. & Visscher, P. M. Response to Browning and Browning. *Am. J. Hum. Genet.* **89**, 191-195 (2011).

- 40 Yang, J. *et al.* Genome partitioning of genetic variation for complex traits using
common SNPs. *Nature genetics* **43**, 519-U544 (2011).
- 41 Lee, S. H. *et al.* Estimation and partitioning of polygenic variation captured by
common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. *Human
molecular genetics* **22**, 832-841 (2012).
- 42 Constantino, J. N. & Todd, R. D. Intergenerational transmission of subthreshold
autistic traits in the general population. *Biological psychiatry* **57**, 655-660,
doi:10.1016/j.biopsych.2004.12.014 (2005).
- 43 Franke, A. *et al.* Genome-wide meta-analysis increases to 71 the number of
confirmed Crohn's disease susceptibility loci. *Nat. Genet.* **42**, 1118-1125 (2010).
- 44 Loftus, E. V., Jr. *et al.* Increased risks of developing anxiety and depression in young
patients with Crohn's disease. *Am. J. Gastroenterol.* **106**, 1670-1677 (2011).
- 45 Kohane, I. S. *et al.* The co-morbidity burden of children and young adults with autism
spectrum disorders. *PLoS one* **7**, e33224 (2012).
- 46 Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000
cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661-678
(2007).
- 47 Benach, J. L., Li, E. & McGovern, M. M. A microbial association with autism. *mBio* **3**
(2012).
- 48 Wray, N. R., Lee, S. H. & Kendler, K. S. Impact of diagnostic misclassification on
estimation of genetic correlations using genome-wide genotypes. *Eur. J. Hum.
Genet.* (2012).
- 49 Bromet, E. J. *et al.* Diagnostic Shifts During the Decade Following First Admission for
Psychosis. *Am. J. Psychiatry* (2011).
- 50 Laursen, T. M., Agerbo, E. & Pedersen, C. B. Bipolar Disorder, Schizoaffective
Disorder, and Schizophrenia Overlap: A New Comorbidity Index. *J. Clin. Psychiatry*
79, 1432-1438 (2009).
- 51 Tsuang, M. T., Woolson, R. F., Winokur, G. & Crowe, R. R. Stability of psychiatric
diagnosis. Schizophrenia and affective disorders followed up over a 30- to 40-year
period. *Arch. Gen. Psychiatry* **38**, 535-539 (1981).
- 52 Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS
discovery. *Am. J. Hum. Genet.* **90**, 7-24, doi:10.1016/j.ajhg.2011.11.029 (2012).
- 53 Wray, N. R. *et al.* Genome-wide association study of major depressive disorder: new
results, meta-analysis, and lessons learned. *Mol. Psychiatry* **17**, 36-48 (2012).
- 54 Falconer, D. & Mackay, T. *Introduction to Quantitative Genetics*. Fourth edn,
(Longman, 1996).
- 55 Van Snellenberg, J. X. & de Candia, T. Meta-analytic evidence for familial
coaggregation of schizophrenia and bipolar disorder. *Arch. Gen. Psychiatry* **66**, 748-
755 (2009).
- 56 Lichtenstein, P. *et al.* Common genetic determinants of schizophrenia and bipolar
disorder in Swedish families: a population-based study. *Lancet* **373**, 234-239 (2009).
- 57 McGuffin, P. *et al.* The heritability of bipolar affective disorder and the genetic
relationship to unipolar depression. *Arch. Gen. Psychiatry* **60**, 497-502 (2003).
- 58 Moreno-De-Luca, D. *et al.* Deletion 17q12 Is a Recurrent Copy Number Variant that
Confers High Risk of Autism and Schizophrenia *American journal of human genetics*
88, 121-121 (2011).
- 59 Stankiewicz, P. & Lupski, J. R. Structural Variation in the Human Genome and its Role
in Disease. *Ann. Rev. Med.* **61**, 437-455 (2010).
- 60 Nijmeijer, J. S. *et al.* Identifying loci for the overlap between attention-
deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide
QTL linkage approach. *J. Am. Acad. Child Adolesc. Psychiatry* **49**, 675-685 (2010).

- 61 Mulligan, A. *et al.* Autism symptoms in Attention-Deficit/Hyperactivity Disorder: a familial trait which correlates with conduct, oppositional defiant, language and motor disorders. *J. Autism Dev. Disord.* **39**, 197-209 (2009).
- 62 Ripke, S. *e. a.* Genome-wide association of schizophrenia in Sweden. *Nature genetics* **In press** (2013).
- 63 Sullivan, P. F., Daly, M. J. & O'Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nature reviews. Genetics* **13**, 537-551 (2012).
- 64 Reich, T., James, J. W. & Morris, C. A. The use of multiple thresholds in determining the mode of transmission of semi-continuous traits. *Ann Hum Genet* **36**, 163-184 (1972).
- 65 Cochran, W. G. The combination of estimates from different experiments. *Biometrics* **10**, 101-129 (1954).
- 66 Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ* **327**, 557-560 (2003).
- 67 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for Genome-wide Complex Trait Analysis. *Am. J. Hum. Genet.* **88**, 76-82 (2011).

S Hong Lee¹, Stephan Ripke^{2,3}, Benjamin M Neale^{2,3}, Stephen V Faraone^{4,5}, Shaun M Purcell^{2,3,6}, Roy H Perlis^{3,7}, Bryan J Mowry^{1,8}, Anita Thapar⁹, Michael E Goddard^{10,11}, John S Witte¹², Devin Absher¹³, Ingrid Agartz^{14,15}, Huda Akil¹⁶, Farooq Amin¹⁷, Ole A Andreassen^{14,18}, Adebayo Anjorin¹⁹, Richard Anney²⁰, Verner Anttila², Dan E Arking²¹, Philip Asherson²², Maria H Azevedo²³, Lena Backlund²⁴, Judith A Badner²⁵, Anthony J Bailey²⁶, Tobias Banaschewski²⁷, Jack D Barchas²⁸, Michael R Barnes²⁹, Thomas B Barrett³⁰, Nicholas Bass^{31,32}, Agatino Battaglia³³, Michael Bauer³⁴, Mònica Bayés³⁵, Frank Bellivier^{36,37,38,39}, Sarah E Bergen^{3,7,40}, Wade Berrettini⁴¹, Catalina Betancur^{42,43,44}, Thomas Bettecken⁴⁵, Joseph Biederman⁴⁶, Elisabeth B Binder⁴⁵, Donald W Black⁴⁷, Douglas H R Blackwood⁴⁸, Cinnamon S Bloss⁴⁹, Michael Boehnke⁵⁰, Dorret I Boomsma^{51,52,53}, Gerome Breen^{22,54,55}, René Breuer⁵⁶, Richard Bruggeman⁵⁷, Nancy G Buccola⁵⁸, Jan K Buitelaar⁵⁹, William E Bunney⁶⁰, Joseph D Buxbaum⁶, William F Byerley^{61,62}, Enda M Byrne¹, Sian Caesar⁶³, Wiepke Cahn^{64,65}, Rita M Cantor⁶⁶, Miguel Casas^{67,68}, Aravinda Chakravarti²¹, Kimberly Chambert³, Khalid Choudhury⁶⁹, Sven Cichon^{70,71,72}, C Robert Cloninger⁷³, David A Collier²², Edwin H Cook⁷⁴, Hilary Coon⁷⁵, Bru Cormand^{76,77,78}, Aiden Corvin²⁰, William H Coryell⁴⁷, David W Craig⁷⁹, Ian W Craig²², Jennifer Crosbie⁸⁰, Michael L Cuccaro⁸¹, David Curtis⁸², Darina Czamara^{45,83}, Susmita Datta⁸⁴, Geraldine Dawson^{85,86,87}, Richard Day⁸⁸, Eco J De Geus^{51,52,53}, Franziska Degenhardt^{70,72}, Srdjan Djurovic^{14,89}, Gary J Donohoe²⁰, Alysia E Doyle⁹⁰, Jubao Duan⁹¹, Frank Dudbridge⁹², Eftichia Duketis⁹³, Richard P Ebstein⁹⁴, Howard J Edenberg^{95,96}, Josephine Elia^{41,97}, Sean Ennis⁹⁸, Bruno Etain^{36,39,99,100}, Ayman Fanous^{101,102}, Anne E Farmer²², I Nicol Ferrier¹⁰³, Matthew Flickinger⁵⁰, Eric Fombonne^{104,105}, Tatiana Foroud⁹⁶, Josef Frank⁵⁶, Barbara Franke⁵⁹, Christine Fraser^{106,107}, Robert Freedman¹⁰⁸, Nelson B Freimer¹⁰⁹, Christine M Freitag⁹³, Marion Friedl¹¹⁰, Louise Frisén¹¹¹, Louise Gallagher¹¹², Pablo V Gejman⁹¹, Lyudmila Georgieva^{106,107}, Elliot S Gershon¹¹³, Daniel H Geschwind^{114,115}, Ina Giegling¹¹⁰, Michael Gill²⁰, Scott D Gordon¹¹⁶, Katherine Gordon-Smith^{63,117}, Elaine K Green¹¹⁸, Tiffany A Greenwood¹¹⁹, Dorothy E Grice⁶, Magdalena Gross¹²⁰, Detelina Grozeva¹¹⁷, Weihua Guan⁵⁰, Hugh Gurling^{19,32}, Lieuwe De Haan¹²¹, Jonathan L Haines¹²², Hakon Hakonarson^{123,124}, Joachim Hallmayer¹²⁵, Steven P Hamilton⁶¹, Marian L Hamshere^{117,126}, Thomas F Hansen¹²⁷, Annette M Hartmann¹¹⁰, Martin Hautzinger¹²⁸, Andrew C Heath⁷³, Anjali K Henders¹¹⁶, Stefan Herms⁷⁰, Ian B Hickie¹²⁹, Maria Hipolito¹³⁰, Susanne Hoefels¹²⁰, Peter A Holmans^{117,126}, Florian Holsboer⁴⁵, Witte J Hoogendijk¹³¹, Jouke-Jan Hottenga^{51,53}, Christina M Hultman⁴⁰, Vanessa Hus¹³², Andrés Ingason¹²⁷, Marcus Ising⁴⁵, Stéphane Jamain^{36,39,99,100}, Edward G Jones¹³³, Ian Jones¹¹⁷, Lisa Jones⁶³, Tzeng Jung-Ying¹³⁴, Anna K Kähler⁴⁰, René S Kahn¹³⁵, Radhika Kandaswamy¹⁹, Matthew C Keller¹³⁶, James L Kennedy¹³⁷, Elaine Kenny²⁰, Lindsey Kent¹³⁸, Yunjung Kim¹³⁹, George K Kirov^{106,107}, Sabine M Klauck¹⁴⁰, Lambertus Klei¹⁴¹, James A Knowles¹⁴², Martin A Kohli⁴⁵, Daniel L Koller⁹⁶, Bettina Konte¹¹⁰, Ania Korszun¹⁴³, Lydia Krabbendam^{65,144}, Robert Krasucki¹⁴⁵, Jonna Kuntsi²², Phoenix Kwan¹⁴⁶, Mikael Landén^{40,147}, Niklas Långström⁴⁰, Mark Lathrop¹⁴⁸, Jacob Lawrence^{32,149}, William B Lawson¹³⁰, Marion Leboyer^{36,39,99,100}, David H Ledbetter¹⁵⁰, Phil Hyoun Lee⁷, Todd Lencz^{151,152,153}, Klaus-Peter Lesch^{154,155}, Douglas F Levinson¹⁵⁶, Cathryn M Lewis²², Jun Li¹⁵⁷, Paul Lichtenstein⁴⁰, Jeffrey A Lieberman¹⁵⁸, Dan-Yu Lin¹⁵⁹, Don H Linszen^{65,160}, Chunyu Liu²⁵, Falk W Lohoff⁴¹, Sandra K Loo^{161,162}, Catherine Lord¹⁶³, Jennifer K Lowe^{114,115}, Susanne Lucae⁴⁵, Donald J MacIntyre⁴⁸, Pamela AF Madden¹⁶⁴, Elena Maestrini¹⁶⁵, Patrik KE Magnusson⁴⁰, Pamela B Mahon¹⁶⁶, Wolfgang Maier¹²⁰, Anil K Malhotra^{151,152,153}, Shrikant M Mane¹⁶⁷, Christa L Martin¹⁵⁰, Nicholas G Martin¹¹⁶, Manuel Mattheisen^{168,169,170}, Keith Matthews⁸⁸, Morten Mattingsdal^{14,171}, Steven A McCarroll³, Kevin A McGhee⁴⁸, James J McGough¹⁷², Patrick J McGrath¹⁷³, Peter McGuffin²², Melvin G McInnis¹⁷⁴, Andrew McIntosh^{48,175}, Rebecca McKinney¹⁷⁶, Alan W McLean^{48,175}, Francis J McMahon¹⁷⁷, William M McMahon¹⁷⁸, Andrew McQuillin^{19,32}, Helena Medeiros¹⁷⁹, Sarah E Medland¹¹⁶, Sandra Meier⁵⁶, Ingrid Melle^{14,18}, Fan Meng¹⁶, Jobst Meyer¹⁸⁰, Christel M Middeldorp^{51,53}, Lefkos Middleton¹⁸¹, Vihra Milanova¹⁸², Ana Miranda¹⁸³, Anthony P Monaco^{184,185}, Grant W Montgomery¹¹⁶, Jennifer L Moran³, Daniel Moreno-De-Luca¹⁸⁶, Gunnar Morken^{187,188}, Derek W Morris²⁰, Eric M Morrow^{189,190}, Valentina Moskvina^{117,126}, Pierandrea Muglia¹⁷⁶, Thomas W Mühleisen^{72,191}, Walter J Muir^{48,175}, Bertram Müller-Myhsok^{45,83}, Michael Murtha^{192,193,194}, Richard M Myers¹³, Inez Myin-Germeys^{65,144}, Michael C Neale¹⁰², Stan F Nelson¹⁶², Caroline M Nievergelt¹¹⁹, Ivan Nikolov^{106,107}, Vishwajit Nimgaonkar^{195,196}, Willem A Nolen¹⁹⁷, Markus M Nöthen^{70,72}, John I Nurnberger¹⁹⁸, Evaristus A Nwulia¹³⁰, Dale R Nyholt¹¹⁶, Colm O'Dushlaine³, Robert D Oades¹⁹⁹, Ann Olincy¹⁰⁸, Guiomar Oliveira^{23,200}, Line Olsen¹²⁷, Roel A Ophoff^{109,201,202}, Urban Osby¹¹¹, Michael J Owen^{106,107}, Aarno Palotie²⁰³, Jeremy R Parr¹⁰³, Andrew D Paterson^{204,205}, Carlos N Pato¹⁷⁹, Michele T Pato¹⁷⁹, Brenda W Penninx^{52,53,206}, Michele L Pergadia¹⁶⁴, Margaret A Pericak-Vance⁸¹, Benjamin S Pickard^{48,175}, Jonathan Pimm¹⁴⁵, Joseph Piven²⁰⁷, Danielle Posthuma^{208,209,210}, James B Potash⁴⁷,

Fritz Poustka⁹³, Peter Propping⁷², Vinay Puri¹⁴⁵, Digby J Quested²¹¹, Emma M Quinn²⁰, Josep Antoni Ramos-Quiroga^{67,68}, Henrik B Rasmussen^{127,212}, Soumya Raychaudhuri^{2,3}, Karola Rehnström²⁰³, Andreas Reif²¹³, Marta Ribasés^{214,215}, John P Rice²¹⁶, Marcella Rietschel⁵⁶, Kathryn Roeder²¹⁷, Herbert Roeyers²¹⁸, Lizzy Rossin³, Aribert Rothenberger²¹⁹, Guy Rouleau²²⁰, Douglas Ruderfer⁶, Dan Rujescu¹¹⁰, Alan R Sanders⁹¹, Stephan J Sanders^{186,192,194,221}, Susan Santangelo^{222,223}, Joseph A Sargeant²²⁴, Russell Schachar⁸⁰, Martin Schalling¹¹¹, Alan F Schatzberg²²⁵, William A Scheftner²²⁶, Gerard D Schellenberg²²⁷, Stephen W Scherer²²⁸, Nicholas J Schork^{229,230}, Thomas G Schulze^{166,231}, Johannes Schumacher⁷², Markus Schwarz²³², Edward Scolnick³, Laura J Scott⁵⁰, Jianxin Shi²³³, Paul D Shilling¹⁷⁶, Stanley I Shyn²³⁴, Jeremy M Silverman⁶, Susan L Slager²³⁵, Susan L Smalley²³⁶, Johannes H Smit^{52,237}, Erin N Smith^{229,230}, Edmund JS Sonuga-Barke^{218,238}, David St Clair²³⁹, Matthew State¹⁹², Michael Steffens²⁴⁰, Hans-Christoph Steinhausen^{241,242,243}, John S Strauss²⁴⁴, Jana Strohmaier⁵⁶, T Scott Stroup¹⁵⁸, James Sutcliffe²⁴⁵, Peter Szatmari^{246,247,248}, Szabolcs Szelinger⁷⁹, Srinivasa Thirumalai²⁴⁹, Robert C Thompson¹⁶, Alexandre A Todorov⁷³, Federica Tozzi²⁹, Jens Treutlein⁵⁶, Manfred Uhr⁴⁵, Edwin JCG van den Oord²⁵⁰, Gerard Van Grootheest^{52,237}, Jim Van Os^{65,144}, Astrid M Vicente^{251,252,253}, Veronica J Vieland²⁵⁴, John B Vincent²⁵⁵, Peter M Visscher^{1,256}, Christopher A Walsh^{257,258,259}, Thomas H Wassink⁴⁷, Stanley J Watson¹⁶, Myrna M Weissman²⁶⁰, Thomas Werge¹²⁷, Thomas F Wienker¹¹³, Durk Wiersma⁵⁷, Ellen M Wijsman^{261,262}, Gonneke Willemsen^{51,52}, Nigel Williams^{106,107}, A Jeremy Willsey¹⁹², Stephanie H Witt⁵⁶, Wei Xu²⁰⁵, Allan H Young^{103,263}, Timothy W Yu²⁶⁴, Stanley Zammit^{106,107}, Peter P Zandi²⁶⁵, Peng Zhang^{50,174}, Frans G Zitman²⁶⁶, Sebastian Zöllner^{174,267}, International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)²⁶⁸, Bernie Devlin¹⁴¹, John R Kelsoe^{119,269}, Pamela Sklar⁶, Mark J Daly^{2,3}, Michael C O'Donovan^{106,107}, Nicholas Craddock^{106,107}, Patrick F Sullivan¹³⁹, Jordan W Smoller^{3,7}, Kenneth S Kendler^{102,270,271}, Naomi R Wray^{1,*,†}

¹The University of Queensland, Queensland Brain Institute, Brisbane, QLD, Australia. ¹The University of Queensland, Queensland Brain Institute, Brisbane, QLD, Australia. ²Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ³Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁴Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY. ⁵Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY. ⁶Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA. ⁷Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ⁸Queensland Centre for Mental Health Research, Wacol, Australia. ⁹Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre in Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff University, Cardiff, UK. ¹⁰Biosciences Research Division, Department of Primary Industries Victoria, Melbourne, Victoria, Australia. ¹¹Faculty of Land and Food Resources, University of Melbourne, Melbourne, Victoria, Australia. ¹²Institute for Human Genetics, University of California, San Francisco, CA, USA. ¹³HudsonAlpha Institute of Biotechnology, Huntsville, AL, USA. ¹⁴KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ¹⁵Department of Research, Diakonhjemmet Hospital, Oslo, Norway. ¹⁶Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA. ¹⁷Department of Psychiatry and Behavioral Sciences, Emory University and Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA. ¹⁸Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. ¹⁹Mental Health Sciences Unit, University College London, London, UK. ²⁰Department of Psychiatry, Trinity College Dublin, Dublin, Ireland. ²¹McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²²MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King's College London, London, UK. ²³Faculty of Medicine, University of Coimbra, Coimbra, Portugal. ²⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. ²⁵Department of Psychiatry, University of Chicago, Chicago, IL, USA. ²⁶Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. ²⁷Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ²⁸Department of Psychiatry, Weill Medical College, Cornell University, New York, NY, USA. ²⁹GlaxoSmithKline, London, UK. ³⁰Portland Veterans Affairs Medical Center, Portland, OR, USA. ³¹Molecular Psychiatry Laboratory, Mental Health Sciences Unit, University College London, London, UK. ³²Windeyer Institute of Medical Sciences, London, UK. ³³Stella Maris Institute for Child and Adolescent Neuropsychiatry, 56128 Calambrone (Pisa),

Italy. ³⁴Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Dresden, Germany. ³⁵Centro Nacional de Análisis Genómico (CNAG), Parc Científic de Barcelona (PCB), Catalonia, Spain. ³⁶INSERM, U955, Psychiatrie Génétique, Créteil, France. ³⁷Université Denis Diderot, Paris, France. ³⁸Assistance Publique–Hôpitaux de Paris (AP-HP), GH Saint-Louis, Lariboisière, F Widal, Département de Psychiatrie, Paris, France. ³⁹ENBREC group, Fondation FondaMental, Créteil, France. ⁴⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁴¹Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. ⁴²INSERM U952, Paris, France. ⁴³CNRS UMR 7224, Paris, France. ⁴⁴UPMC University of Paris, Paris, France. ⁴⁵Max Planck Institute of Psychiatry, Munich, Germany. ⁴⁶Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁴⁷Department of Psychiatry, University of Iowa, Iowa City, IA, USA. ⁴⁸Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. ⁴⁹The Scripps Translational Science Institute and Scripps Health, La Jolla, CA, USA. ⁵⁰School of Public Health, University of Michigan, Ann Arbor, MI, USA. ⁵¹Department of Biological Psychology, VU University, Amsterdam, The Netherlands. ⁵²EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. ⁵³Neuroscience Campus Amsterdam, The Netherlands. ⁵⁴National Institute of Health Research Biomedical Research Centre for Mental Health, South London, London, UK. ⁵⁵Maudsley NHS Trust & Institute of Psychiatry, London, UK. ⁵⁶Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ⁵⁷Department of Psychiatry, University of Groningen, Groningen, The Netherlands. ⁵⁸School of Nursing, Louisiana State University Health Sciences Center, New Orleans, LA, USA. ⁵⁹Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands. ⁶⁰Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA. ⁶¹Department of Psychiatry, University of California, San Francisco, CA, USA. ⁶²NCIRE (Northern California Institute of Research And Education), San Francisco, CA, USA. ⁶³Department of Psychiatry, Birmingham University, Birmingham, UK. ⁶⁴Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands. ⁶⁵Netherlands. ⁶⁶David Geffen School of Medicine, University of California, Los Angeles, CA, USA. ⁶⁷Department of Psychiatry, Hospital Universitari Vall d'Hebron, CIBERSAM, Catalonia, Spain. ⁶⁸Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. ⁶⁹Department of Mental Health Sciences, University College London, London, UK. ⁷⁰Department of Genomics, University of Bonn, Bonn, Germany. ⁷¹Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany. ⁷²Institute of Human Genetics, University of Bonn, Bonn, Germany. ⁷³Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. ⁷⁴Institute for Juvenile Research, Department of Psychiatry, University of Illinois, Chicago, IL, USA. ⁷⁵Department of Psychiatry, University of Utah, Salt Lake City, UT. ⁷⁶Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Catalonia, Spain. ⁷⁷Biomedical Network Research Centre on Rare Diseases (CIBERER), Catalonia, Spain. ⁷⁸Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain. ⁷⁹The Translational Genomics Research Institute, Phoenix, AZ, USA. ⁸⁰The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. ⁸¹John P Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA. ⁸²East London NHS Foundation Trust, Queen Mary, University of London, London, UK. ⁸³Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ⁸⁴Genetics Institute, University College London, London, UK. ⁸⁵Autism Speaks, New York, NY, USA. ⁸⁶Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ⁸⁷Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ⁸⁸Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. ⁸⁹Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. ⁹⁰Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁹¹Department of Psychiatry and Behavioral Sciences, NorthShore University Health System and University of Chicago, Evanston, IL, USA. ⁹²Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. ⁹³Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, JW Goethe University Frankfurt, Frankfurt, Germany. ⁹⁴Psychology Department, National University of Singapore, Singapore. ⁹⁵Department of Biochemistry and Molecular Biology, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. ⁹⁶Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. ⁹⁷Al Dupont Hospital for Children, University of Pennsylvania, Philadelphia, PA, USA. ⁹⁸School of Medicine,

Medical Science University College, Dublin, Ireland.⁹⁹ Université Paris Est, Faculté de Médecine, Créteil, France.¹⁰⁰ Assistance Publique—Hôpitaux de Paris (AP-HP), Hôpital H Mondor—A Chenevier, Département de Psychiatrie, Créteil, France.¹⁰¹ Department of Psychiatry, Georgetown University School of Medicine, Washington DC, USA.¹⁰² Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA.¹⁰³ Institutes of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.¹⁰⁴ Department of Psychiatry, Oregon Health & Science University, Portland, OR USA.¹⁰⁵ Institute for Development & Disability, Oregon Health & Science University, Portland, OR USA.¹⁰⁶ MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.¹⁰⁷ Department of Psychological Medicine and Neurology, Cardiff University, Cardiff, UK.¹⁰⁸ Department of Psychiatry, University of Colorado Denver, Aurora, CO, USA.¹⁰⁹ UCLA Center for Neurobehavioral Genetics, University of California, Los Angeles, CA, USA.¹¹⁰ Department of Psychiatry, University of Halle, Halle, Germany.¹¹¹ Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.¹¹² Department of Psychiatry, Trinity College, Dublin, Ireland.¹¹³ Institute of Medical Biometry, University of Bonn, Bonn, Germany.¹¹⁴ Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.¹¹⁵ Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.¹¹⁶ Queensland Institute of Medical Research, Brisbane, QLD, Australia.¹¹⁷ Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.¹¹⁸ Department of Biomedical and Biological Sciences, Plymouth University, Plymouth, UK.¹¹⁹ Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.¹²⁰ Department of Psychiatry, University of Bonn, Bonn, Germany.¹²¹ Department of Psychiatry, AMC, University of Amsterdam The Netherlands.¹²² Center for Human Genetics Research, Vanderbilt University Medical Centre, Nashville, TN, USA.¹²³ The Center for Applied Genomics, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.¹²⁴ Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.¹²⁵ Department of Psychiatry, School of Medicine, Stanford University, Stanford, CA 94305, USA.¹²⁶ Biostatistics and Bioinformatics Unit, Cardiff University, Cardiff, UK.¹²⁷ Institute of Biological Psychiatry, Copenhagen University Hospital, Roskilde, Denmark.¹²⁸ Department of Clinical and Developmental Psychology, Institute of Psychology, University of Tübingen, Tübingen, Germany.¹²⁹ Brain and Mind Research Institute, University of Sydney, Sydney, NSW, Australia.¹³⁰ Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, DC, USA.¹³¹ Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.¹³² Department of Psychology, University of Michigan, Ann Arbor, MI, USA.¹³³ Center for Neuroscience, University of California, Davis, CA, USA.¹³⁴ Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA.¹³⁵ Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands.¹³⁶ Department of Psychology, University of Colorado, Boulder, CO, USA.¹³⁷ Psychiatric Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.¹³⁸ School of Medicine, University of St Andrews, St Andrews, UK.¹³⁹ Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.¹⁴⁰ Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.¹⁴¹ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.¹⁴² University of Southern California, Los Angeles, CA, USA.¹⁴³ Queen Mary University of London, London, UK.¹⁴⁴ Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, Maastricht, The Netherlands.¹⁴⁵ University College London, London, UK.¹⁴⁶ Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.¹⁴⁷ Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.¹⁴⁸ Centre National de Genotypage, Evry, France.¹⁴⁹ Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London Medical School, London, UK.¹⁵⁰ Geisinger Health System, Autism and Developmental Medicine Institute, Danville, PA, USA.¹⁵¹ Department of Psychiatry, Division of Research, The Zucker Hillside Hospital Division of the North Shore, Long Island Jewish Health System, Glen Oaks, NY, USA.¹⁵² Center for Psychiatric Neuroscience, The Feinstein Institute of Medical Research, Manhasset, NY, USA.¹⁵³ Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA.¹⁵⁴ Division of Molecular Psychiatry, ADHD Clinical Research Unit, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany.¹⁵⁵ Department of Neuroscience, School for Mental Health and Neuroscience (MHENS), Maastricht University, The Netherlands.¹⁵⁶ Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.¹⁵⁷ Department of Human Genetics,

University of Michigan, Ann Arbor, MI, USA. ¹⁵⁸Department of Psychiatry, Columbia University, New York, NY, USA. ¹⁵⁹Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA. ¹⁶⁰Department of Psychiatry, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands. ¹⁶¹Department of Psychiatry and Biobehavioral Science, University of California, Los Angeles, CA, USA. ¹⁶²UCLA Center for Neurobehavioral Genetics, University of California, Los Angeles, California, USA. ¹⁶³Center for Autism and the Developing Brain, Weill Cornell Medical College, White Plains, NY, USA. ¹⁶⁴Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. ¹⁶⁵Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy. ¹⁶⁶Department of Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. ¹⁶⁷Yale Center for Genome Analysis, Orange, CT, USA. ¹⁶⁸Department of Biomedicine, Aarhus University, Aarhus C, Denmark. ¹⁶⁹Department of Genomic Mathematics, University of Bonn, Bonn, Germany. ¹⁷⁰Institute of Human Genetics, University of Bonn, Bonn, Germany. ¹⁷¹Sorlandet Hospital HF, Kristiansand, Norway. ¹⁷²University of California, Los Angeles, CA, USA. ¹⁷³New York State Psychiatric Institute, Columbia University, New York, NY, USA. ¹⁷⁴Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. ¹⁷⁵Molecular Medicine Centre, University of Edinburgh, Edinburgh, UK. ¹⁷⁶Neurosciences Centre of Excellence in Drug Discovery, GlaxoSmithKline Research and Development, Verona, Italy. ¹⁷⁷National Institute of Mental Health, US National Institutes of Health, Bethesda, MA, USA. ¹⁷⁸Psychiatry Department, University of Utah Medical School, Salt Lake City, UT, USA. ¹⁷⁹Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ¹⁸⁰Department of Neurobehavioral Genetics, Trier University, Germany. ¹⁸¹Neuroepidemiology and Ageing Research, School of Public Health, Imperial College London, UK. ¹⁸²Department of Psychiatry, First Psychiatric Clinic, Alexander University Hospital, Sofia, Bulgaria. ¹⁸³Department of Developmental and Educational Psychology, University of Valencia, Valencia, Spain. ¹⁸⁴Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ¹⁸⁵Office of the President, Tufts University, Medford MA USA. ¹⁸⁶Department of Psychiatry, Yale University, New Haven, CT, USA. ¹⁸⁷Department of Psychiatry, St Olavs Hospital, Trondheim, Norway. ¹⁸⁸Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. ¹⁸⁹Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA. ¹⁹⁰Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA. ¹⁹¹Life & Brain Center, University of Bonn, Bonn, Germany. ¹⁹²Child Study Center, Yale University, New Haven, CT, USA. ¹⁹³Departments of Psychiatry, Yale University, New Haven, CT, USA. ¹⁹⁴Department of Genetics, Yale University, New Haven, CT, USA. ¹⁹⁵Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. ¹⁹⁶Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA. ¹⁹⁷Groningen University Medical Center, Groningen, The Netherlands. ¹⁹⁸Department of Psychiatry and Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA. ¹⁹⁹Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Essen, Germany. ²⁰⁰Pediatric Hospital, Centro Hospitalar e Universitário Coimbra, Coimbra, Portugal. ²⁰¹Department of Human Genetics, University of California, Los Angeles, CA, USA. ²⁰²Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands. ²⁰³Sanger Institute, Hinxton, Cambridgeshire, UK. ²⁰⁴Program in Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, ON, Canada. ²⁰⁵Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. ²⁰⁶Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. ²⁰⁷University of North Carolina, Chapel Hill, NC, USA. ²⁰⁸Department of Functional Genomics, VU University, Amsterdam, The Netherlands. ²⁰⁹Department of Clinical Genetics, VU Medical Centre, Amsterdam, The Netherlands. ²¹⁰Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. ²¹¹Academic Department of Psychiatry, University of Oxford, Oxford, UK. ²¹²The Lundbeck Initiative for Integrative Psychiatric Research, iPSYCH, Denmark. ²¹³Department of Psychiatry, University of Würzburg, Germany. ²¹⁴Department of Psychiatry, Hospital Universitari Vall d'Hebron, CIBERSAM, Catalonia, Spain. ²¹⁵Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain. ²¹⁶Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, USA. ²¹⁷Department of Statistics, Carnegie Mellon University, Pittsburgh, PA, USA. ²¹⁸Department of Experimental Clinical & Health Psychology, Ghent University, Ghent, Belgium. ²¹⁹Child and Adolescent Psychiatry, University Medicine Göttingen, Göttingen, Germany. ²²⁰Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. ²²¹Program on Neurogenetics, Yale University, New Haven, CT, USA. ²²²Department of Psychiatry, Maine Medical Center, Portland, ME, USA. ²²³Department of Psychiatry, Harvard Medical

School, Boston, MA, USA. ²²⁴Clinical Neuropsychology, VU University, Amsterdam, The Netherlands. ²²⁵Psychiatry and Behavioral Science, Stanford University School of Medicine, Palo Alto, CA, USA. ²²⁶Rush University Medical Center, Chicago, IL, USA. ²²⁷Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²²⁸The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada. ²²⁹The Scripps Translational Science Institute, La Jolla, CA, USA. ²³⁰The Scripps Research Institute, La Jolla, CA, USA. ²³¹Department of Psychiatry & Psychotherapy, University of Göttingen, Göttingen, Germany. ²³²Psychiatric Center Nordbaden, Wiesloch, Germany. ²³³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. ²³⁴Department of Psychiatry and Behavioural Science, University of Washington, Seattle, WA, USA. ²³⁵Mayo Clinic, Rochester, MN, USA. ²³⁶Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. ²³⁷Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. ²³⁸Developmental Brain & Behaviour Laboratory, University of Southampton, Southampton, UK. ²³⁹Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. ²⁴⁰Research Department, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany. ²⁴¹Research Unit of Child and Adolescent Psychiatry, Aalborg University Hospital, Aalborg, Denmark. ²⁴²Clinical Psychology and Epidemiology, University of Basel, Switzerland. ²⁴³Department of Child and Adolescent Psychiatry, University of Zurich, Switzerland. ²⁴⁴Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King's College London, London, UK. ²⁴⁵Vanderbilt University, Nashville, TN, USA. ²⁴⁶Department of Psychiatry University of Toronto, Toronto, Ontario Canada. ²⁴⁷Hospital for Sick Children, Toronto, Ontario Canada. ²⁴⁸Centre for Addiction and Mental Health, Toronto, Ontario Canada. ²⁴⁹West Berkshire NHS Trust, University College London, London, UK. ²⁵⁰Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond, VA, USA. ²⁵¹Instituto Nacional de Saude Dr Ricardo Jorge, Lisbon, Portugal. ²⁵²BioFIG—Center for Biodiversity, Functional and Integrative Genomics, Campus da FCUL, Campo Grande, Lisbon, Portugal. ²⁵³Instituto Gulbenkian de Ciência, Lisbon, Portugal. ²⁵⁴Nationwide Children's Hospital, Columbus, OH, USA. ²⁵⁵Molecular Neuropsychiatry and Development Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada. ²⁵⁶The University of Queensland, Diamantina Institute, Brisbane, QLD, Australia. ²⁵⁷Howard Hughes Medical Institute, Children's Hospital Boston, Boston, MA, USA. ²⁵⁸Division of Genetics, Children's Hospital Boston, Boston, MA, USA. ²⁵⁹Neurology and Pediatrics, Harvard Medical School Center for Life Sciences, Boston, MA, USA. ²⁶⁰Columbia University College of Physicians and Surgeons, New York, NY, USA. ²⁶¹Department of Biostatistics, University of Washington, Seattle, WA, USA. ²⁶²Department of Medicine, University of Washington, Washington, Seattle, WA, USA. ²⁶³Centre for Affective Disorders, Institute of Psychiatry, King's College London, UK. ²⁶⁴Division of Genetics, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA. ²⁶⁵Department of Mental Health, Johns Hopkins University, Baltimore, MD, USA. ²⁶⁶Leiden University Medical Center, Leiden, The Netherlands. ²⁶⁷Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ²⁶⁸A list of members is provided in the Supplementary Note. ²⁶⁹Department of Psychiatry, Special Treatment and Evaluation Program (STEP), Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. ²⁷⁰Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA. ²⁷¹Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA. * These authors contributed equally.

¶Correspondence should be addressed to N.R.W (naomi.wray@uq.edu.au).